Hydrophobic Matrix Drug Delivery Paste
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug-delivery methods face challenges in achieving controlled, spatial, and temporal distribution of high molecular weight pharmaceutical agents, such as biotherapeutics, due to breakdown in the digestive tract or blood system, leading to suboptimal delivery and bioavailability issues.
Innovation Solution
A method involving the creation of a paste-like or semi-solid drug-delivery composition by mixing a hydrophobic matrix with pharmaceutically active compounds, using mechanical treatment like pressing and folding to achieve sustained release, while maintaining the biological activity of sensitive molecules like proteins and peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional oral or parenteral dosage forms are used to deliver high molecular weight APIs, then the delivery method is simple and easy to administer, but the bioavailability is poor and the spatial-temporal control of drug distribution is lost due to breakdown in digestive tract or blood system
Solution Approach 1:
The patent changes the physical and chemical parameters of the delivery system by using a hydrophobic matrix with specific viscosity (10-1000 Pa·s) and incorporating APIs at controlled concentrations (0.1-50% w/w). This parameter optimization protects biotherapeutics from degradation while maintaining deliverability, resolving the contradiction between reliability and complexity.
Solution Approach 2:
The patent creates a composite material system combining a hydrophobic matrix (such as waxes, lipids, or synthetic polymers) with pharmaceutically active compounds. This composite structure provides both protection for the API and controlled release capability, improving bioavailability without requiring overly complex delivery mechanisms.
2Manufacturing precision
If polymeric micro- and nano-particles are used for controlled delivery of biotherapeutics, then spatial-temporal control is improved, but the particles can diffuse in and out of target tissue, be attacked by macrophages, or be rapidly cleared by the reticuloendothelial system
Solution Approach 1:
The patent applies local quality by creating a hydrophobic matrix with specific local properties (viscosity, hydrophobicity) that interact differently with various components. The matrix provides localized protection for embedded APIs while maintaining overall structural integrity, achieving both precision control and delivery stability.
Solution Approach 2:
The patent employs a disposable hydrophobic matrix system that is designed for single-use delivery. The matrix degrades or releases its payload in a controlled manner and is then eliminated, avoiding the need for complex retrieval mechanisms and reducing the risk of long-term accumulation or immune response.
3Duration of action of moving object
If a hydrophobic matrix is mixed with pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition, then prolonged and controlled release is achieved with protected biological activity, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-forming the hydrophobic matrix with appropriate viscosity characteristics before incorporating the API. This preliminary preparation ensures that the matrix is ready to provide controlled release from the start, simplifying the overall manufacturing process while achieving prolonged drug release.
Solution Approach 2:
The patent optimizes the viscosity parameter of the hydrophobic matrix (10-1000 Pa·s) to achieve the right balance between manufacturability and controlled release performance. By carefully controlling this parameter, the system enables prolonged drug release without requiring excessively complex manufacturing procedures.
4Quantity of substance
If the concentration of pharmaceutically active compound is increased in the hydrophobic matrix, then the therapeutic effect is enhanced, but the homogeneity of distribution and bioavailability may be compromised
Solution Approach 1:
The patent optimizes the concentration parameter of API within the hydrophobic matrix, specifying ranges (0.1-50% w/w) that balance therapeutic efficacy with homogeneous distribution. This parameter optimization ensures that sufficient drug is delivered while maintaining uniform dispersion for reliable bioavailability.
Solution Approach 2:
The patent emphasizes achieving homogeneous distribution of API within the hydrophobic matrix through proper mixing and formulation techniques. This homogeneity ensures consistent drug release and predictable therapeutic effects, even at higher API concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables prolonged and controlled release of therapeutic agents, protecting their biological activity and improving bioavailability by forming a homogeneous distribution within a hydrophobic matrix, which can be applied in various forms for targeted delivery.
Implementation Method 1
a hydrophobic matrix, wherein the paste-like or semi-solid mixture has a viscosity of 10-1000 Pa·s
Data Source
AI summary
A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.